Improved Non-Invasive Biomechanical Evaluation Method for the Virtue of Risedronate


Article Preview

New medicines for treatment of osteoporotic bones have developed. In the previous studies, there were lots of pre-clinical experiments on animals to analyze the virtue of new medicine. However, the previous methods sacrificed a number of animals. They induced lots of expenses and ethical problems. In the present study, to investigate the effect of a medicine for osteoporosis by using in-vivo micro computed tomography (In-vivo Micro-CT, skyscan 1076, skyscan, Belgium) and micro finite element (*FE) analysis, morphological and mechanical characteristic changes of rat bone were detected and tracked. The 8 female Sprague-Dawley rats, used in the experiment, were randomized into 3 groups (Control, Sham and Risedronate group). The Risedronate (actonel, 0.58mg/Kg and 5days/week) for 8 weeks was administered in RIS group. The 4th lumbar vertebrae of rats were scanned by In-vivo Micro-CT with 35*m at week 0 (just before dose) and week 8 (after dose). Three-dimensional (3D) structural parameters were calculated. Simulated compression tests of 3D FE models were carried out to investigate the mechanical characteristics in the whole vertebral bone model of the 4th lumbar vertebra. The change rate of quantity and structure in Risedronate (RIS) group was smaller than that of control (CON) group. The change rate of structural modulus in RIS group was also smaller than that of CON group. This result shows the virtue of risedronate quantitatively as well as qualitatively. The study introduced the improved noninvasive biomechanical evaluation method, combined with In-vivo Micro-CT and *FE analysis, which was more effective and useful than the previous pre-clinical experiments.



Key Engineering Materials (Volumes 342-343)

Edited by:

Young-Ha Kim, Chong-Su Cho, Inn-Kyu Kang, Suk Young Kim and Oh Hyeong Kwon




C. Y. Ko et al., "Improved Non-Invasive Biomechanical Evaluation Method for the Virtue of Risedronate", Key Engineering Materials, Vols. 342-343, pp. 921-924, 2007

Online since:

July 2007




[1] M. Stevenson, M. Lloyd Jones, E. Nigris, N. Brewer, S. Davis and J. Oakley : A systemtic review and economic evalution on alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis (Health Technology Assessment, UK 2005).

DOI: 10.3310/hta9220

[2] National Institutes of Health: NIH Conensus Statement : Osteoporosis Prevention, Diagnosis, and Therapy (NIH, USA 2000).

[3] M. Ito, A. Nishida, K. Aoyagi, M. Uetani, K. Hayashi and M. Kawase: Effects of risedronate on trabecular microstructure and biomechanical properties in ovariectomized rat tibia. Osteoporos Int. Vol. 16 (2005), pp.1042-1048.

DOI: 10.1007/s00198-004-1802-3

[4] B. Borah, T. E. Dufresne, P. A. Chmielewski, G. J. Gross, M. C. Prenger, and R. J. Phipps: Risedronate Preservers Trabecular Architecture and Increases Bone Strength in Vertebra of Ovaricetomized Minipigs as Measured by Three-Dimensional Microcomputed Tomography J. Bone Miner. Res. Vol. 17(7)(2002).

DOI: 10.1359/jbmr.2002.17.7.1139

[5] N.A. Sims, H.A. Morris, R.J. Moore, T.C. Durbridge: Increased bone resorption precedes increased formation in the ovariectomized rat Calcif Tissue Int. Vol. 59(1996), pp.121-127.

DOI: 10.1007/s002239900098

[6] T.J. Wronski, M. Clintron, L.M. Dann: Temporal relationship between bone loss and increased bone turnover in ovariectomized rat Calcif Tissue Int. Vol. 43(1988), pp.179-183.

DOI: 10.1007/bf02571317

[7] D.N. Kalu: The ovariectomized rat model of postmenopausal bone loss Bone Miner. Vol. 15(1991), 175-192.

DOI: 10.1016/0169-6009(91)90124-i

[8] D.G. Woo, H.S. Kim, Y.Y. Won, M.H. Baek and G.R. Tack: The elatstic and plastic behavior of the micro-FE models for vertebral trabecular bones The conference of KSPE 1 st, p.1320~1323, (2003).

[9] J.H. Kinney, D.L. Haupt, M. Balooch, A.J.C. Ladd, J.T. Ryaby and N.E. Lane: ThreeDimensional Morphometry of the L6 Vertebra in the Ovariectomized Rat Model of Osteoporosis: Biomechanical Implications J. Bone Miner. Res. Vol. 15(10)(2000).

DOI: 10.1359/jbmr.2000.15.10.1981

[10] R.W. Boyce, C.L. Paddock, J.R. Gleaso, W.K. Sletsema, and E.F. Eriksen: The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site J. Bone Miner. Res. Vol. 10(1995).

DOI: 10.1002/jbmr.5650100207

Fetching data from Crossref.
This may take some time to load.